Evidence map›Paper›PMID 41703369›Full record

ArticleHepatology international2026

TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study.

Xue-Gang Yang, Li-Wei Deng, Yong Zhao, Bo Peng, Bin Liu, Shi-Feng Feng, Dong-Xu Liu, Jun-Feng Liu, Yan-Yuan Sun, Yan Chen and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xue-Gang Yang *Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Li-Wei Deng *Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Yong Zhao *Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.
Bo Peng *Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China.
Bin Liu *Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China.
Shi-Feng FengDepartment of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.
Dong-Xu LiuDepartment of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.
Jun-Feng LiuDepartment of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Yan-Yuan SunDepartment of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Yan ChenDepartment of pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Chang-Li LiaoDepartment of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Chi ZhangDepartment of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Le LiuDepartment of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China.
Lei CaoDepartment of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China. 327511253@qq.com.
Yi RenDepartment of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China. ir_cd_2nd_ph@sina.com.
Guo WeiDepartment of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China. weiguo69@sohu.com.
Guo-Hui XuDepartment of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. xgh0913@hotmail.com.

Funding

Natural Science Foundation of Sichuan 2025ZNSFSC0239
6 · The paper itself

Abstract

BACKGROUND AND

aimsThis study aimed to evaluate the efficacy and safety of combining transarterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs), with or without programmed death-1 (PD-1) inhibitors (ICI), as first-line therapy for intermediate-advanced hepatocellular carcinoma (HCC) in a real-world setting.

methodsThis multicentre retrospective cohort study enrolled patients with intermediate-advanced HCC who received either TACE combined with TKIs and PD-1 inhibitors (TACE-TKI-ICI) or TACE plus TKIs (TACE-TKI) from January 2019 to December 2023. The outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Propensity score matching (PSM) was used to reduce bias.

resultsA total of 514 patients with intermediate-advanced HCC were analyzed, 263 patients in the TACE-TKI-ICI group and 251 patients in the TACE-TKI group. After PSM (1:1), 241 patients were included in each group. The TACE-TKI-ICI group had significantly longer median PFS (13.8 vs. 10.8 months; hazard ratio [HR] = 0.73; 95% confidence interval [CI], 0.58-0.91; p = 0.005) and OS (22.6 vs. 16.7 months; HR = 0.71; 95% CI, 0.55-0.91; p = 0.006) than the TACE-TKI group. The ORR was also better (58.9% vs. 41.5%, p < 0.001) in the TACE-TKI-ICI group. The incidence of grade 3/4 adverse events was 10.8% in the TACE-TKI-ICI group and 8.3% in the TACE-TKI group.

conclusionAdding PD-1 inhibitors to TACE and TKIs as first-line therapy for intermediate-advanced HCC can improve PFS, OS, and ORR, while being well tolerated.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticImmune Checkpoint InhibitorsLiver NeoplasmsProtein Kinase InhibitorsAgedCombined Modality TherapyFemaleHumansMaleMiddle AgedProgrammed Cell Death 1 ReceptorRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsHepatocellular carcinomaImmunologic checkpoint inhibitorsProgrammed cell death 1 receptor (PD-1)Transarterial chemoembolizationTyrosine kinase inhibitors

Identifiers

PMID41703369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.